On December 22, 2025, the FDA approved oral semaglutide for weight loss under the brand name Wegovy. It was the first GLP-1 pill approved for chronic weight management in the United States — a formulation milestone years in development, solving the bioavailability problem that had made oral delivery of peptide drugs commercially impractical for decades. Ten weeks later, approximately 400,000 Americans are taking it daily. [1] [2]

CNN called the uptake "dramatic." The word does not fully capture the speed. The fastest-adopted drugs in recent American pharmaceutical history — statins, proton pump inhibitors — built comparable user bases over quarters, not weeks. The Wegovy pill's trajectory suggests the injection was the primary barrier to GLP-1 adoption for a substantial population, not the cost, the appetite suppression, or the weekly commitment. [1] [3]

The clinical signal embedded in the uptake data is significant. A Reuters study published in February found that more than a third of Wegovy pill patients were new to GLP-1 drugs entirely — not switchers from injections but people who had not previously taken any GLP-1 therapy. [4] That profile of the new Wegovy pill patient is not a semaglutide veteran seeking a more convenient delivery format. It is someone who was waiting for a pill.

The AAMC, reporting in early March, documented primary care and endocrinologist prescribing patterns: within three weeks of the January 5 launch, 60 percent of primary care physicians named the Wegovy pill as a top-of-mind weight loss therapy — up from 14 percent just months before. The shift in prescribing patterns from specialist-driven to primary care-accessible is itself a structural change in how GLP-1 drugs enter American households. [3]

The efficacy data is modest compared with injection semaglutide. The phase 3 trial for the highest dose showed 16.6 percent weight loss at 64 weeks, compared with 20-plus percent for the injectable formulation at similar timepoints. [2] The cardiovascular outcome data — the evidence base that has made injectable GLP-1s a cardiological treatment, not merely a weight loss drug — does not yet exist for the pill formulation.

That gap matters, given the cardiovascular risk research on what happens when GLP-1 users stop. The 400,000 Americans on the pill are accumulating a treatment duration that will, eventually, create discontinuation events. What happens to patients who start the pill form, which offers a lower efficacy ceiling, if they stop it — whether for cost, tolerability, or formulary reasons — is not yet known. The cardiovascular risk literature was built on injectable users. The pill creates a new population, with a different clinical profile, whose long-term discontinuation risk has not been measured.

Novo Nordisk built a drug that 400,000 Americans adopted in ten weeks. The question of what those 400,000 people now require — in sustained access, in clinical monitoring, in institutional support for a medication they may need indefinitely — is the question the adoption rate does not answer.